Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 4/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1826678 | 0.91 | MTNR1B (0.52) | MTNR1BMTNR1AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL7802403 | 0.91 | ALDH1A1 (0.50) | MTNR1BMTNR1AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL7802198 | 0.88 | HSD17B10 (0.49) | MTNR1BMTNR1AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL7804798 | 0.87 | MTNR1A (0.48) | MTNR1BMTNR1AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL1827316 | 0.84 | MAPT (0.53) | MTNR1BMTNR1AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL6382370 | 0.83 | MAPT (0.58) | MTNR1BMTNR1AALDH1A1MAPTHSD17B1 | |
| SCHEMBL8951604 | 0.82 | LCK (0.56) | MTNR1BMTNR1AHSD17B10 | |
| SCHEMBL7804155 | 0.81 | HSD17B10 (0.51) | MTNR1BMTNR1AALDH1A1HSD17B10MAPT | |
| SCHEMBL11374252 | 0.80 | MAPT (0.62) | KDM4EALDH1A1HSD17B10PLK1PLK3 | |
| SCHEMBL6377507 | 0.78 | MTNR1A (0.59) | MTNR1BMTNR1AALDH1A1HSD17B10HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461205-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120283326-A1 | ANTHRANILIC ACID DERIVATIVES | CHELSEA THERAPEUTICS, INC. | 2012-11-08 | — | — | US | disclosed |
| US-8263658-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2118051-B1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS INC (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20100029767-A1 | ANTHRANILIC ACID DERIVATIVES | Chelsea Therapeutics, Inc | 2010-02-04 | — | — | US | disclosed |
| EP-2118051-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | Chelsea Therapeutics, Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008097180-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| EP-1720825-B1 | ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS | ACTIVE BIOTECH AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| US-7074831-B2 | Compounds, methods for their preparation and use thereof | ACTIVE BIOTECH AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20050187297-A1 | New compounds, methods for their preparation and use thereof | ACTIVE BIOTECH AB (SE) | 2005-08-25 | — | — | US | disclosed |
| EP-0815087-B1 | TRISUBSTITUTED PHENYL DERIVATIVES | NOVARTIS AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| US-5990116-A | USE IN PREVENTION OR TREATMENT OF INFLAMMATORY AND PROLIFERATIVE SKIN DISEASES AND CANCER; COMPOUNDS SUCH AS 6-(2-(2,5-DIMETHOXYPHENYL)ETHYL)-4-ETHYL-QUINAZOLINE | NOVARTIS AG (CH) | 1999-11-23 | — | — | US | disclosed |
| EP-0815087-A1 | TRISUBSTITUTED PHENYL DERIVATIVES | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996028430-A1 | TRISUBSTITUTED PHENYL DERIVATIVES | NOVARTIS AG (CH) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283326-A1 | ANTHRANILIC ACID DERIVATIVES | ACOX3, BCL3, AOC3 | MTNR1B 2588/4885MTNR1A 1988/4885KDM4E 4207/4885 |
| US-20100029767-A1 | ANTHRANILIC ACID DERIVATIVES | ACOX3, BCL3, AOC3 | MTNR1B 2602/4885MTNR1A 2006/4885KDM4E 4172/4885 |
| US-20050187297-A1 | New compounds, methods for their preparation and use thereof | MALT1, TPMT, FUCA1 | MTNR1B 1361/4885MTNR1A 2327/4885KDM4E 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.